Most of diabetic cardiovascular complications are attributed to endothelial dysfunction and impaired angiogenesis. Endoplasmic Reticulum (ER) and oxidative stresses were shown to play a pivotal role in the development of endothelial dysfunction in diabetes. Hemeoxygenase-1 (HO-1) was shown to protect against oxidative stress in diabetes; however, its role in alleviating ER stress-induced endothelial dysfunction remains not fully elucidated. We aim here to test the protective role of HO-1 against high glucose-mediated ER stress and endothelial dysfunction and understand the underlying mechanisms with special emphasis on oxidative stress, inflammation and cell death.
Introduction
Endothelial dysfunction generally refers to structural and functional impairment of endothelium including damage at the cellular level. It plays a key role in the pathogenesis of various cardiovascular diseases, such as atherosclerosis, diabetic complications, and hypertension. Heme oxygenase (HO) is one of the cyto-protective proteins that could confer a beneficial effect in vasculature. HO originally functions as a rate-limiting enzyme in heme degradation, yielding carbon monoxide (CO), iron, and biliverdin as the end products. HO-1 and HO-2 are isoforms of HO in mammals [1] . The HO-2 isoform is constitutively expressed; however, HO-1 is an inducible one. HO-1 expression can be induced by many structurally different molecules and by cellular stress such as heat shock [2] . In particular, the role of HO-1 as a protective enzyme is well known. Its anti-oxidant, anti-apoptotic, and antiinflammatory effects have been extensively studied [2, 3] . The cyto-protective effect of HO-1 may have several distinct underlying mechanisms, including the degradation of heme to the anti-oxidant bilirubin, the co-ordinate induction of ferritin, which chelates the pro-oxidant free iron, and release of carbon monoxide (CO), which exerts significant anti-inflammatory and antiapoptotic effects [4] .
HO-1 can be induced by numerous oxidizing agents and stimuli, including ultraviolet radiation, heavy metals, cytokines and heme/ hemoglobin [2, 5] . It is now well established that HO-1 can provide anti-oxidation and cyto-protection in in vitro and in vivo systems. There is convincing evidence indicating that HO-1 can protect the vasculature against remodelling and endothelial dysfunction [6] . Furthermore, HO-1 is currently regarded as a novel therapeutic target in the treatment of vascular disease, and several strategies have been employed to target this enzyme in the vasculature. A variety of pharmacological agents of different chemical structures have been shown to protect against the development of vascular disease in numerous studies in vivo [7, 8] . Moreover, Yang et al. [9] demonstrated the anti-oxidant protective role of HO-1 in vitro by reducing endogenous reactive oxygen species (ROS) production in HUVECs when grown in serum from rats exposed to cigarette smoke [9] . Concerning the anti-inflammatory role of HO-1, Chang et al. [10] successfully highlighted this role in HUVECs treated with iodine-based contrast medium that was used as an inflammatory model in this study. They showed that HO-1 induction reduced ICAM-1 and adhesion molecules receptor expression [10] . About the anti-apoptotic effects of HO-1, Abraham et al. [11] have previously reported that the overexpression of HO-1 in human dermal microvessel endothelial cells prevented high glucose-mediated slowdown of cell cycle progression and increase in apoptosis [11] . Utilizing Zucker diabetic fat rats (ZDF), it has also been reported that the induction of HO-1 expression at the early stages of diabetes using cobalt protoporphyrin (CoPP) and stannous chloride (SnCl 2 ) improved blood pressure and reduced endothelial cell sloughing and strongly upregulated anti-apoptotic signals including Bcl-xl and Bcl-2 [12] .
Despite the cyto-protective effects of HO-1 that have been welldocumented in literature, the role it plays with regard to ER stress response which has been shown in recent years to be involved in the pathophysiology of insulin resistance/diabetes [13] and in the development of endothelial dysfunction [14] is not fully elucidated. The ER is the site of protein secreted synthesis and folding. Upon disruption in protein folding or modification within the ER, a state of stress ensues, resulting in the unfolded protein response (UPR) with the aim to return the ER to its physiological state and enhance cell survival [15] [16] [17] . The UPR functions via signalling through three stress-sensing proteins found on the ER membrane: PKR-like eukaryotic initiation factor 2a kinase (PERK), inositolrequiring kinase-1a (IRE-1a), and activating transcription factor (ATF)-6. The ER luminal domains of PERK, IRE-1a, and ATF-6 interact with the ER chaperone Binding immunoglobulin protein (BiP). BiP is responsible for maintaining the effectors of UPR response under inactive form. Under stress conditions, accumulation of misfolded or unfolded proteins within the ER, BiP dissociates from these sensor proteins, which thereby become active. However, prolonged UPR activation leads to apoptosis, oxidative stress, and inflammation and is referred to as the ''ER stress response". Diabetes results in metabolic conditions that increase the demand on the ER for protein and lipid synthesis [15] . Several studies including ours have shown that insulin resistant states such as obesity promote ER stress response in various tissues such as liver, adipose tissue, and the heart [13, 18, 19] .
Activated PERK phosphorylates, and thus activates, eIF (eukaryotic initiation factor)-2a, thereby reducing general protein translation. However, the translation of ATF-4 is selectively permitted. ATF-4 is required for the expression of pro-apoptotic CCAAT/ enhancer-binding protein homologous protein (CHOP) transcription factor that plays a key role in ER stress-mediated cell dysfunction. CHOP upregulates the expression of pro-apoptotic proteins such as Bim, and downregulates the expression of anti-apoptotic molecule Bcl-2 [16, 17] . ER stress causes insulin resistance and participates in the low-grade inflammation observed in insulin resistant states [13, 20] by mediating cell death and the activation of inflammatory pathways such as nuclear factor-jB (NF-jB) and cJun N-terminal kinase (JNK) [15] . An association between ER stress and endothelial dysfunction was reported in experimental models of diabetes [14, 21] ; however, the underpinning mechanisms are unclear especially regarding the role of ER stress mediated inflammation and cell death.
The aim of this study was to show in the context of a high glucose environment, how HO-1 induction would affect ER stressinduced endothelial dysfunction and angiogenic capacity in endothelial cells. As such, we hypothesized that HO-1 would reduce ER stress response activity and hence improve ER stressmediated inflammation, oxidative stress and apoptosis, which are major molecular contributors to endothelial dysfunction, the initial step in the development of atherosclerosis.
By using human vascular endothelial cells as a model, we provide evidence that HO-1 induction exerts a protective role against ER stress-mediated endothelial dysfunction and impaired angiogenic capacity caused by high glucose treatment. The effects of HO-1 induction involve several protective mechanisms including the alleviation of oxidative stress in addition to inflammatory and apoptotic responses induced by ER stress activation. We show here, the critical role of ER stress-mediated cell death in diabetesinduced endothelial dysfunction and impaired angiogenic capacity. These results underscore the role of HO-1 induction as a key modulator for ER stress response in metabolic disorders and diabetes.
Materials & methods

Cell culture and treatments
Human Umbilical Vein Endothelial cells (HUVECs) were obtained from Life Technologies (Paisley, UK) and were routinely cultivated in M200 medium (Gibco, Paisley, UK) supplemented with low serum growth supplement (LSGS; Gibco, Paisley, UK) containing 2% of foetal bovine serum and were maintained at 37°C in a humidified atmosphere with 5% CO 2 . Cells were used for experiments up to passage 6.
To assess the effects of high glucose on endothelial cells, HUVECs were incubated either with culture medium containing a physiological concentration of glucose (5 mM) or cultured in high glucose (33 mM) for 5 days with intermittent recovery periods of 8 h with medium containing 5 mM of glucose [16 h in high glucose (33 mM) followed by 8 h in normal glucose (5 mM) for 5 consecutive days]. M200 culture medium was supplemented with Dglucose (SigmaAldrich, Gillingham, UK) to the desired concentration. To factor out the osmotic stress effect which high glucose treatments may have on cells, mannitol (SigmaAldrich, Gillingham, UK) was used as an osmotic stress control where control groups of HUVECs were treated in similar fashion to the high glucose group, with medium supplemented with mannitol (33 mM) with 8 h recovery periods for 5 days.
To [22] .
To assess the involvement of ER stress response, some cells were treated with the chemical chaperone, 4-Phenyl Butyric Acid (PBA, 10 mM; SigmaAldrich, Gillingham, UK) to inhibit ER stress [20] . PBA was added to cells 1 h before the last high glucose treatment and then kept for an additional 12 h before the harvest.
As a positive control for oxidative stress, some cells were trea- E. coli serotype O111:B4) 1 lg/ml (Cell Signalling by NEB, Hitchin, UK) at 1 lg/ml for 8 h prior to assessing IL-6 release in culture medium by ELISA (ThermoScientific, Loughborough, UK).
Total RNA isolation and gene expression analysis
After incubation of HUVECs with high glucose in the presence or absence of modulators of ER stress response or HO-1 inducer, total RNA was isolated using Qiagen RNeasy mini kit (Qiagen, Manchester, UK) following the manufacturer's protocol.
Before cDNA synthesis, total RNA was treated with DNAase I to digest any excess genomic DNA. First strand cDNA was synthesized from 1 lg of total RNA employing the RevertAid First Strand cDNA Synthesis Kit (ThermoScientific, Loughborough, UK) and an oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer as reverse primer. Then, target genes were amplified by real-time PCR using GoTaq qPCR Master Mix (Promega, Southampton, UK) in Applied Biosystems 7500 Real-Time PCR System (ThermoScientific, Loughborough, UK).
Total cDNA samples with known quantities in ng (100 ng/ll, 10 ng/ll, 1.0 ng/ll, 0.1 ng/ll and 0.01 ng/ll) were prepared from HUVECs stimulated with thapsigargin. These samples were used to generate standard curves for genes of interest. These standard curves were then used to determine the relative mRNA expression levels in HUVECs.
Primer pairs for target genes were obtained from Primer bank. Human primer sequences used in the study are as follows:
Western blotting
After cell treatments, whole-cell lysates were prepared by extraction in radioimmuno-precipitation assay (RIPA) (10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% SDS; 1% Triton-X100; 1% Sodium deoxycholate; 1 mM NaF; 5 mM EDTA; 1 mM sodium orthovanadate; cocktail of protease inhibitors) as described previously [18, 23] . Proteins of equal amounts (10-20 lg) were then separated on 8-12% SDS-PAGE gels (ThermoScientific, Loughborough, UK). Immunoblots were performed using antibodies against: ATF-4, p-eIF-a (Ser51), caspase 3, cleaved caspase 3, caspase 7, 
Assessment of cell death
Cell apoptosis was assessed by flow cytometry analysis using an Annexin V Apoptosis Detection Kit APC (eBioscience, Altrincham, UK) as described previously [24] . Briefly, after treatments, cells were collected by trypsinization and were re-suspended in incubation buffer containing Annexin V-PE and propidium iodide (1 lg/ ml), incubated in the dark at 4°C for 10 min, and then fixed in 1% formaldehyde. Cells were then re-suspended in incubation buffer and analysed in a BD FACSCanto TM II (BD Bioscience, Oxford, UK). Cell apoptosis was expressed as the percentage of apoptotic cells expressed as the total number of cells. Some cells were treated with Staurosporine (1 lM; SigmaAldrich, Gillingham, UK) for 3 h and were used as a positive control for apoptosis while untreated cells were used a negative control.
Caspases 3/7 activity
HUVECs were cultured in physiological concentration of glucose (5 mM) or in intermittent high glucose (5/33 mM) for 5 days in the absence or presence of PBA or CoPP. As positive control, some cells were treated with Staurosporine (1 mM) for 3 h while untreated cells were used as a negative control. Then, caspases 3/7 activity was measured using Caspase-Glo Ò 3/7 Assay (Promega, Southampton, UK) according to the manufacturer's guidelines. Caspase-Glo Ò 3/7 reagent contains a luminogenic substrate (Aminoluciferin) attached to tetra-peptide sequence Z-DEVD, which is specific for protease cleavage by caspases 3 and 7. Caspases 3 and 7 cleave Z-DEVD releasing Aminoluciferin which is a luminescent substrate for the luciferase reaction. The light output from the luciferase reaction is directly proportional to the activity of the enzymes. The activity of caspases 3 and 7 was determined using a LUMIstar Omega luminometer (BMG LABTECH, Aylesbury, UK).
ELISA analysis of IL-6 production
HUVECs were incubated in physiological concentration of glucose (5 mM) or in intermittent high glucose (5/33 mM) for 5 days in the presence or absence of CoPP (10 lM) and/or SnPP (20 lM).
A positive control was generated by treating some cells with lipopolysaccharide (LPS; Cell Signalling by NEB, Hitchin, UK) at 1 lg/mL for 30 min. Supernatants were collected and centrifuged at 10,000g for 10 min to remove dead cells and any debris and then assayed for IL-6 using an ELISA kit (ThermoScientific, Loughborough, UK) according to the manufacturer's instructions.
Nitrite and nitrate measurement by Griess assay
The production of NO was also quantified by measuring the released NO metabolites (nitrite and nitrates) with Griess reagent (Life Technologies, Loughborough, UK). The Griess assay was used to measure the concentration of nitrite/nitrate that are stable byproducts of NO degradation as an indirect way of estimating the production of NO in HUVECs. Culture medium samples were collected from control and high glucose-treated cells in the presence or absence of PBA or CoPP. Culture medium samples were then centrifuged to remove dead cells and cell debris. The medium was subsequently processed to determine nitrate and nitrite concentrations according to the manufacturer's protocol [25] .
ROS measurement by dihydroethidine (DHE) staining
HUVECs were cultured in physiological concentration of glucose (5 mM) or in intermittent high glucose (5/33 mM) for 5 days in the absence or presence of PBA or CoPP. As a positive control, H 2 O 2 (100 lM) was added to some cells for 30 min to induce ROS release. Osmotic stress was controlled by growing cells in medium where glucose was replaced by mannitol (33 mM). Following this, cells were washed three times with phosphate buffer salt (PBS) solution, and then incubated with the oxidative fluorescent dye DHE (10 lM; SigmaAldrich, Gillingham, UK) for 30 min. Cells were then harvested, washed three times with PBS and then fluorescence at 620 nm was determined and the number of DHEpositive cells was calculated using a FACSCanto TM II flow cytometer (BD Bioscience, Oxford, UK). Negative and positive cells were then plotted using the positive control and DHE negative cells (untreated cells). Cells shifting to the right channel were considered as positive for DHE [25, 26] .
2.9. In vitro tube-like structure formation assay on matrigel Ò matrix
HUVECs were incubated in physiological concentration of glucose (5 mM) or in intermittent high glucose (33 mM) for 5 days in the presence or absence of PBA or CoPP. Then, they were seeded (10 5 cells per well) on 24-well culture plates coated with a basement membrane preparation extracted from Engelbreth-HolmSwarm murine sarcoma (Matrigel Ò ; BD Bioscience, Oxford, UK) [27] . Briefly, 250 lL of Matrigel Ò substrate diluted with serumfree medium (1:1 dilution) was added into each well of 24-well plates and allowed to solidify for 1 h at 37°C. Then, cells were incubated with M200 medium supplemented with LSGS and allowed to adhere for 1 h. Untreated cells cultured in M200 medium without LSGS were used as the negative control, while those cultured in M200 medium supplemented with the LSGS that has 2% FBS + 3 ng/mL b-FGF were used as positive control. HUVECs were incubated for further 24 h and tube-like structures formation was examined using an inverted phase contrast microscope. Then, using ImageJ software, the length of the tubes formed was counted in 5 different blind fields, averaged then compared across the different samples.
Assessment of HO-1 activity (bilirubin assay)
Bilirubin colorimetric assay kit (Cell Biolabs Inc., San Diego, CA, USA) was used to measure the total and direct bilirubin levels in HUVECs' lysates following the manufacturer's protocol. Briefly, HUVECs were cultured in normal glucose (5 mM) or exposed intermittently to high glucose (5/33 mM) for 5 days in the presence or absence of CoPP (10 lM) or SnPP (20 lM). Then, cells were lysed with RIPA lysis buffer and centrifuged at 10,000g for 10 min at 4°C. Bilirubin standards were prepared in 1:2 serial dilutions. Samples and standards were then loaded in duplicates in a 96-well micro-plate. Accelerant (proprietary reagent) was added to each well. Diazo reagent was then loaded to samples and standards. Reagent A (Sodium hydroxide) was then added to all wells and the plate left for incubation for 1 h at room temperature protected from light. After incubation is over, assay reagent B was added and absorbance at 540 nm was measured. The net OD for each sample was calculated by subtracting OD from negative control wells from each sample well, which was then plotted against standard curve to determine bilirubin levels (mg/dL).
Cell viability assay
This viability assay is based on the capacity of metabolically active alive cells to covert the yellow tetrazolium salt 3-(4,5-dime thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to purple formazan crystals. This allows a quantitative evaluation of viable cells. HUVECs were seeded into 96-well plates at the density of 20,000 cells per well and then grown for 24 h. Following this, cells were incubated with varying concentrations of CoPP (10, 25, 50, 75 and 100 lM) for either 12 or 24 h. After incubation, we added MTT (SigmaAldrich, Gillingham, UK) at final concentration of 0.5 mg/mL to each wells and incubated cells for further 4 h at 37°C. Then, culture medium was removed and 100 lL of Dimethyl sulfoxide (SigmaAldrich, Gillingham, UK) was added to each well to solubilise the formazan crystals and incubated for further 30 min at 37°C. Absorbance was then measured at 570 nm using a multi-plate reader (Molecular Devices, Wokingham, UK). The intensity of colour in control wells was used to indicate 100% of viability.
Data analysis
Results are expressed as mean ± SEM, and n represents the number of mice or biological replicates. Statistical analyses were performed using ANOVA (2-way or 1-way, as appropriate) followed by Tukey's or Bonferroni's multiple comparison post hoc tests. P < 0.05 was considered to be statistically significant.
Results
Validation of the conditions of induction of HO-1 by CoPP in HUVECs
To validate the optimal conditions for use of CoPP to induce HO-1 in HUVECs and to ensure that the increase in protein levels is indeed reflecting an increase in activity, we conducted a series of experiments. We first constructed a dose-and time-course response to varying concentrations of CoPP to determine the optimal concentration and time for the induction of HO-1 in HUVECs without causing any non-specific toxicity to the cells. Once determined, we evaluated the activity of HO-1 in response to CoPP treatment.
As shown in Fig. 1A , the incubation of cells with CoPP at the concentrations of 10, 25, 50, 75 and 100 lM all caused an increase in protein expression of HO-1 after 12 and 24 h; however, the increase was higher at 12 h. Furthermore, as shown in Fig. 1B , the incubation of HUVECs with these different concentrations of CoPP for 12 and 24 h caused a significant decrease in cell viability at 24 h in all concentrations; however, at 12 h, none of these concentrations showed a significant decrease in cell viability. Altogether, we decided for this project to induce HO-1 expression by treating cells with CoPP at the concentration of 10 lM for 12 h.
To ascertain that HO-1 expression reflects an increase in its activity, we have assessed the enzyme's activity by measuring the release of heme degradation by-product bilirubin in cells exposed or not to high glucose in the presence or absence of CoPP, a HO-1 inducer, and/or SnPP, a HO inhibitor. As shown in Fig. 1C , high glucose did not affect bilirubin levels while the induction of HO-1 by CoPP (10 lM, 12 h) caused an increase of its release indicating an increase in HO-1 activity in HUVECs. The pre-treatment of cells with SnPP partially, but significantly, prevented the increase in bilirubin caused by CoPP. These data indicate that in our hands the induction of HO-1 by CoPP reflects an increase of the enzymes activity.
HO-1 induction prevents the induction of ER stress response in HUVECs caused by high glucose treatment
As expected, intermittent high glucose (33 mM) treatment of HUVECs for 5 days induced an activation of ER stress response. As shown in Fig. 2 (A, B and C) , high glucose caused an increase in mRNA expression of BiP, CHOP and ATF-4 to levels comparable to positive control thapsigargin. The pre-treatment of cells with PBA to inhibit ER stress prevented the increase in mRNA expression of these key ER stress markers ( Fig. 2A, B and C) . At the protein level, similarly to thapsigargin treatment, the incubation of HUVECs with intermittent high glucose enhanced the phosphorylation of e-IF2-a and increased protein expression of both BiP ( Fig. 2D and E) and ATF-4 (Fig. 2F) . Although mannitol caused a moderate increase in the phosphorylation of e-IF2-a, it did not affect the activation of other key ER stress response markers excluding thus any contribution of osmotic stress in high glucose-mediated ER stress response. HO-1 induction by CoPP prevented the activation of ER stress response in HUVECs as evidenced by the normalisation of e-IF2-a phosphorylation and reduction in BiP and ATF-4 protein expression (Fig. 2D, E and F) indicating a protective role for HO-1 against high glucose-induced ER stress in HUVECs.
HO-1 induction prevents oxidative stress caused by high glucose treatment in HUVECs
The incubation of HUVECs with intermittent high glucose treatment for 5 days caused a significant increase in ROS production compared to negative control (Fig. 3A) . HO-1 induction by CoPP significantly reduced ROS production to control levels (Fig. 3A) indicating the protective role that HO-1 has against high glucoseinduced oxidative stress. Mannitol failed to show any increase in ROS production indicating that these effects shown with high glucose treatment are due to metabolic stress and not osmotic stress. PBA treatment also significantly reduced ROS production caused by high glucose although not to the same extent as CoPP (Fig. 3A) . These data indicate a considerable degree of ER stress involvement in high glucose-mediated increase in ROS production.
NADPH oxidase system is an important source of ROS production in the vasculature particularly in endothelial cells [28] . As shown in Fig. 3B , when HUVECs were subjected to high glucose (33 mM for 5 days with intermittent recovery periods), there was a significant increase in the phosphorylation of p47 phox regulatory subunit when compared to control condition; whereas, cotreatment of cells with CoPP has resulted in a significant reversal of such effect. The phosphorylation of regulatory subunit p47 phox is believed to be a prerequisite for the activation of NADPH oxidase complex [29] . The induction of ER stress response by thapsigargin also enhanced the phosphorylation of p47 phox and this effect was prevented by the pre-incubation of cells with PBA, again indicating the involvement of ER stress in this process.
HO-1 induction prevents ER stress-mediated activation of proinflammatory signalling pathways caused by high glucose
Intermittent treatment of HUVECs with high glucose for 5 days significantly increased the phosphorylation of inflammatory markers iKK a/b (Fig. 4A) and c-JUN (Fig. 4B) compared to control. This Histograms represent pooled normalized data to negative control (CTL) (n = 3-6 per group). (C), HO-1 activity assay showing bilirubin production (mg/dL) in HUVECs incubated in physiological (5 mM) concentration of glucose or in intermittent high glucose (5/33 mM) for 5 days in the presence or absence of CoPP or SnPP (n = 3). Data are presented as mean ± SEM and were analysed by one-way ANOVA, followed with Tukey's multiple comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. control or indicated groups. CTL, control; HG, high glucose.
effect was also noticeable with thapsigargin treatment and reversed by PBA indicating the involvement of ER stress in this process. When adding PBA to the cells incubated with high glucose, similarly to thapsigargin this has prevented the increase in phos- in this inflammatory response, cells were treated with mannitol which did not affect neither the expression nor the activation of inflammatory molecules investigated ( Fig. 4A and B) . In order to ascertain the protective role that HO-1 has against high glucose-induced inflammatory response in HUVECs, we assessed the production of a key pro-inflammatory cytokine IL-6. As shown in Fig. 4C , similarly to thapsigargin, IL-6 mRNA levels have significantly increased after the treatment of cells with intermittent high glucose compared to controls. This increase was significantly reversed back to control levels with PBA treatment indicating ER stress involvement in this process (Fig. 4C) . HO-1 induction by CoPP reversed the increase in IL-6 mRNA expression both in high glucose and thapsigargin-treated HUVECs to bring them back to control levels (Fig. 4C ). This suggests that the antioxidant activity of HO-1 plays a protective role against high glucoseinduced inflammation, at least partly, through the alleviation of ER stress response. Furthermore, ELISA analysis of IL-6 protein release in culture medium collected from HUVECs showed a significant elevation in IL-6 levels in high glucose culture medium compared to control (Fig. 4D) . However, culture medium harvested from HUVECs treated with high glucose in the presence of CoPP showed similar levels of IL-6 expression to negative control clearly indicating a protective effect of HO-1 induction against high glucosemediated inflammation. When SnPP (20 lM), a heme analogue inhibitor of HO, was added 1 h before CoPP treatment, this has negated CoPP effects on high glucose-mediated increase of IL-6 release (Fig. 4D) .
HO-1 induction prevents ER stress-mediated apoptosis caused by high glucose treatment in HUVECs: critical role for caspases 3 and 7
Analysis of apoptosis by flow cytometry showed that amongst HUVECs cultured in intermittent high glucose conditions, the percentage of apoptotic cells significantly increased to 45% compared to 7% in HUVECs cultured in medium with physiological glucose concentration (Fig. 5) . However, the percentage of apoptotic cells amongst HUVECs cultured in intermittent high glucose media was significantly reduced to 15% after HO-1 induction with CoPP treatment (Fig. 5) . To further emphasize the anti-apoptotic effect of HO-1 induction, SnPP, a HO inhibitor (20 lM), was added 1 h prior to adding CoPP to HUVECs incubated with high glucose. SnPP reversed the protective effects of HO-1 with a significant increase in percentage of apoptotic cells to 40% (Fig. 5) , thus providing further evidence on the protective effect of HO-1 against apoptosis in high glucose milieu and indicating the key role of ER stress in this process.
To further understand the mechanisms underlying the protective role of HO-1 against high glucose-induced apoptosis, we assessed the enzymatic activity of caspases 3/7. As shown in Fig. 6A , HUVECs cultured in intermittent high glucose (33 mM) conditions showed a significant increase in caspases 3/7 activity compared to negative control. This effect was negated by CoPP treatment bringing caspases 3/7 activity levels to those of the negative control.
Furthermore, we determined by western blot analysis the expression of active (cleaved) caspases 3/7 and PARP (a caspase-3 substrate). As shown in Fig. 6B , HUVECs incubated with high glucose medium (33 mM) exhibited cleavage of caspases 3/7 and PARP indicating the activation of these pro-apoptotic subpathways. Similar observations were also noticeable with thapsigargin treatment. When adding PBA to cells incubated with high glucose, this has prevented the cleavage of caspases 3/7 and PARP indicating that high glucose-induced apoptotic response involves ER stress response induction (Fig. 6B) .
Furthermore, we analysed the cleavage of these three proapoptotic effectors (PARP and caspases 3/7) following the treatment of HUVECs with H 2 O 2 (100 lM) for 30 min. H 2 O 2 caused the cleavage of PARP and caspases 3/7 and this effect was abolished by HO-1 induction with CoPP treatment. Cells incubated with high glucose and where HO-1 was induced by CoPP showed no cleavage of these proteins indicating the protective role HO-1 plays against oxidative stress-mediated apoptosis (Fig. 6B) . When cells were treated with mannitol, no cleavage of caspases 3/7 or PARP was observed which excludes the involvement of osmotic stress in this apoptotic response.
Altogether, our data show that HO-1 induction was able to prevent apoptosis triggered by oxidative stress and ER stress response following exposure of endothelial cells to high glucose. These effects were related to the inhibition of NF-jB and JNK proapoptotic and inflammatory pathways, alleviation of ER stress response particularly the reduction of CHOP expression and to preventing the cleavage of caspases 3/7 and PARP, which play a key central role in the final steps of different apoptosis cascades.
Alleviation of high glucose-induced ER stress by HO-1 induction improves endothelial function and angiogenic capacity in HUVECs
As shown in Fig. 7A , high glucose treatment decreased NO production in HUVECs while the induction of HO-1 prevented this effect increasing thus NO bioavailability considering the concomitant decrease in ROS observed previously (Fig. 3) . Furthermore, western blot analysis of key components of NO pathway, showed that HO-1 induction by CoPP strongly enhanced the phosphorylation of eNOS on its key activatory site (Ser1177) and the phosphorylation of Akt (Ser473) (Fig. 7B and C) indicating the activation of Akt/eNOS that is involved in the positive regulation of NO release. As presented in Fig. 7D , HO-1 expression was successfully induced by CoPP treatment (10 lM) while high glucose (33 mM) did not affect the protein's expression.
As depicted in Fig. 8A , HUVECs treated intermittently with high glucose for 5 days showed a significant reduction in tube-like structure formation compared to positive control. This effect was reversed by PBA treatment with significant increase in tube-like structure formation compared to high glucose alone indicating the involvement of ER stress in this process (Fig. 8A) . Moreover, similar protective effect was noticeable with HO-1 induction by CoPP indicating its protective pro-angiogenic role and antagonising the effects of high glucose-induced ER stress. This pro-angiogenic effect of HO-1 induction was further supported by the observation that CoPP treatment also caused an increase in mRNA (Fig. 8B) and protein ( Fig. 8C ) expression of the key pro-angiogenic factor VEGF-A in endothelial cells. Altogether, these findings provide evidence that the protective role of HO-1 induction by CoPP against impaired angiogenesis caused by high glucose in HUVECs is carried out by activating the pro-angiogenic VEGF-A-p-eNOS/P-AKT-NO axis and the attenuation of ER stress response.
Discussion
In this study, we provide evidence that HO-1 induction exerts a protective role against ER stress-mediated endothelial dysfunction and impaired angiogenic capacity caused by high glucose treatment. The effects of HO-1 induction involve several protective mechanisms including the alleviation of oxidative stress in addition to inflammatory and apoptotic responses induced by ER stress activation. High glucose-mediated ER stress response is believed to play a key role in different aspects of endothelial dysfunction both in humans and in animal models of diabetes. High glucose induces ER stress response and ROS production in a close interplay, which ultimately may contribute to the pathogenesis of micro-and macro-vascular complications, associated with diabetes [30, 31] . Recently, mice injected with streptozotocin to cause diabetes exhibited enhanced ER stress response in the heart and small mesenteric arteries. Treatment of these mice with a chemical chaperone (Tauroursodeoxycholic acid, TUDCA) improved endothelium-dependent and -independent relaxation. We report here that exposure of HUVECs to high glucose caused an increase in both mRNA and protein expression of key ER stress markers (phospho-eIF2-a, BiP, CHOP and ATF-4) indicating that the upstream ER stress arm PERK/eIF2-a is activated under these conditions. PERK is the major effector controlling the attenuation of protein translation when ER stress ensues through the activation of the elongation factor, eIF2-a. Activation of eIF2a allows for selective translation of ATF-4 that regulates the expression of the pro-apoptotic factor CHOP. We also report that similarly to chemical chaperone PBA, the induction of HO-1 by CoPP, reversed the effects of high glucose on ER stress indicating an important cross talk between ROS and ER stress in these conditions. Consistent with our observations, Kim et al. [32] have reported that the induction of HO-1 through the exposure of HUVECs to CO or CoPP prevented thapsigargin-induced expression of CHOP [32] .
Mannitol, however, caused a moderate increase in the expression phospho-eIF2-a without affecting the expression of other ER stress markers. This is possibly because mannitol may have enhanced a transient need for more protein synthesis and hence caused a transient activation of UPR response.
During ER stress, several mechanisms can lead to increased ROS production including the ER itself, which becomes an important source of ROS due to the inhibition of protein translation by the PERK/eIF2-a/ATF-4 pathway, in addition to the activation of NADPH oxidase complex [33] . As expected, we found here that high glucose-mediated ER stress increased ROS production in HUVECs that was blunted by HO-1 induction and PBA indicating a strong interplay between ER stress and ROS in high glucose conditions. NADPH oxidase is a major source of ROS production in the vasculature [28] . Amongst other important regulatory mechanisms, the phosphorylation of p47 phox regulatory subunit was shown to be a prerequisite for the activation of NADPH oxidase [29] . We observed here that the phosphorylation of p47 phox at Ser345 was enhanced in cells exposed intermittently to high glucose suggesting the activation of NADPH oxidase complex. [35] . However, the exact role of this phosphorylation and the activation of NADPH oxidase warrants further investigation to establish a clear mechanistic link between HO-1, ER stress and activation of NADPH oxidase. Much evidence links ER stress with major inflammatory signalling hubs. For instance, PERK/ eIF2-a/ATF-4 arm of ER stress triggers the activation of JNK which is involved in the positive regulation of some inflammatory genes and apoptosis [33] . In our hands, high glucose-mediated ER stress was associated with the activation of JNK and NF-jB pathways and caused a significant increase in the production of IL-6 inflammatory cytokine. All these effects were counteracted by HO-1 induction and the inhibition of ER stress indicating the involvement of ROS either upstream and/or downstream of ER stress in this process. Inflammatory response has been mechanistically linked to oxidative stress [36, 37] . Consistent with our findings, previous studies indicated that hyperglycaemia triggers the generation of free radicals which activate NFjB that is known to induce the up-regulation of other proinflammatory cytokines including IL-6, which can in turn activate ER stress response by a vicious cycle and contribute to the maintenance of the inflammatory state during ER stress [38] .
We observed here that HO-1 induction alleviated the effects of high glucose in activating several pro-apoptotic pathways, in which ER stress is central, including the activation of JNK and PERK/eIF2-a/ATF-4/CHOP pathways. Several mechanisms controlling cell death following unresolved ER stress have been reported most of which have been prevented by HO-1 induction in the present study [39] . In prolonged ER stress, IRE-1a sensor can cause the phosphorylation and activation of JNK, which can ultimately induce apoptosis [16] . When ER stress becomes severe, the PERK/ eIF2a/ATF-4 pathway also activates the transcription factor CHOP, which upregulates the expression of pro-apoptotic proteins such as Bim, and downregulates the expression of anti-apoptotic molecule Bcl-2 [16, 17] .
Consistent with other studies, we report here that the activation of JNK and PERK/eIF2-a/ATF-4/CHOP axis caused by high glucose was associated with a high apoptosis rate in HUVECs [40] . HO-1 induction or inhibition of ER stress prevented the activation of these pro-apoptotic signals, which was translated into a reduction of apoptosis. These findings further highlight the important antiapoptotic role of HO-1. Endogenous HO-1 induction was observed in HUVECs exposed to high glucose levels up to 10 mM; however, higher concentrations of glucose (>20 mM) did cause a significant downregulation of HO-1 expression which was linked to an increase in apoptosis rate [40] . Another study by Abraham et al. [11] also found that the incubation of endothelial cells with high glucose (33 mM) for 7 days caused a decrease in HO activity and protein expression [11] . This suggests that HO-1 levels are critical to overcome the pro-apoptotic effects of high glucose. In our study and consistent with these previous studies, we found that high glucose (33 mM) did not induce HO-1 expression or activity. We observed that these high concentrations of glucose (33 mM) failed to increase apoptosis in HUVECs in the presence of HO-1 inducer, CoPP, indicating a therapeutic potential for HO-1 induction against high glucose-mediated endothelial apoptosis. These pro-survival effects of HO-1 are directly linked to the enzyme's activity because the treatment of HUVECs with SnPP, a potent HO inhibitor, reversed the beneficial effects of HO-1 induction on cell survival.
An important feature of apoptosis is the activation of caspases where the Bcl-2 family plays a crucial role in regulating their engagement under ER stress [41] . In our study, we observed that HO-1 induction protected HUVECs against high glucose-induced activation of caspases 3 and 7. Consistent with our results, it was found that under ER stress conditions, through the action of JNKdependent signalling, caspase-3 cleavage and activity is enhanced leading to high levels of calcium in the mitochondria [42] . In our study, the activation of caspase-3 effector is consistent with the activation by high glucose of PERK/eIF2-a/ATF-4/CHOP pathway.
Perturbations in angiogenesis are tightly linked to endothelial dysfunction and contribute to ischemic complications of diabetes. HO-1 was found to possess potent pro-angiogenic properties. The overexpression of HO-1 in endothelial cells was reported to enhance cell proliferation and tube formation capacity [43] . We report here for the first time that HO-1 induction and inhibition of ER stress in HUVECs prevented the impairment of capillarylike structure formation on Matrigel assay caused by intermittent high glucose treatment indicating the involvement of ER stress in this process and the therapeutic potential of HO-1 induction against high glucose-mediated ischemia. In line with our findings, a number of studies implicated ER stress in endothelial dysfunction and impaired angiogenic capacity. For instance, the chemical chaperone TUDCA was shown to protect against impaired ischemiainduced neovascularization following hind-limb ischemia after femoral artery ligation in db/db diabetic mice [44] . Endothelial dysfunction plays a key role in diabetic microvascular dysfunction because endothelial NO is a crucial regulator of angiogenic sprouting [45] . We report here that HO-1 induction and ER stress inhibition improved NO production and enhanced the activation of Akt/ eNOS pathway in HUVECs exposed to high glucose, which eventually contributes to restoring the capacity of cells to form tube-like structures. The concomitant reduction of ROS production in cells treated with CoPP or PBA also contributes to the improved NO bioavailability. ER stress can affect NO bioavailability through several ways and hence impair angiogenic capacity of endothelial cells. Accumulation of CHOP was shown to inhibit eNOS synthesis through a direct interaction with the enzyme's promoter while CHOP-deficient mice exhibited an improved postnatal ischemiainduced neovascularization [46] . ER stress can also affect endothelial NO bioavailability by causing endothelial insulin resistance which may directly and negatively affect endothelial function. Insulin by binding to its receptor, expressed by endothelial cells, can stimulate the release of NO by endothelial cells [47] , and, thus, endothelial insulin resistance can impair insulin-mediated NO release [48] . Ozcan et al. reported that the activation of ER stress enhanced NF-jB and JNK pathways, which then phosphorylated insulin receptor substrate (IRS)-1 on serine residues and hence blunted insulin signalling response [13] . In our study, we found that high glucose-mediated ER stress was closely associated with the activation of NF-jB and JNK pathways, which may in turn contribute to the impairment of endothelial insulin response.
Although, the role that heme degradation by-products play in the cyto-protective effects of HO-1 in our system was not specifically studied, some evidence in the literature indicate that the action of both bilirubin and CO may alleviate ER stress response; however, their exact role needs to be further delineated in future studies. Biliverdin and bilirubin are both potent antioxidants through a direct ROS scavenging mechanism and were found to prevent oxidative stress-mediated cell death [49] . Recently, bilirubin was shown to enhance insulin signalling response in a dietinduced obesity mouse model and in db/db diabetic mice through the suppression of ER stress response [50] . Bilirubin levels in humans were found to be associated with reduced risk for coronary heart disease [49, 51] . CO, the other degradation by-product, was found to prevent apoptosis in endothelial cells by activating p38 MAP kinase. CO was also shown to improve insulin response by increasing intracellular calcium [49] . Recently, it was reported that CO-releasing agent, CORM-2, improved ER stress response and blocked ER stress-mediated impairment in leptin signalling in cells treated with ER stress inducers thapsigargin and tunicamycin [52] .
Altogether, we demonstrate in the present study the pivotal role of ER stress-mediated cell death in high glucose-induced endothelial dysfunction and impaired angiogenic capacity and underscore the potential role of HO-1 induction as a key therapeutic modulator for ER stress response in ischemic disorders and diabetes.
